Skip to content
Aerami Therapeutics

Aerami Therapeutics

Reimagining the treatment of chronic diseases with Inhaled Therapies

  • ABOUT US
  • Inhalation Technology
  • Pipeline
  • INVESTORS + MEDIA
  • CONTACT
  • linkedin
  • twitter

Seeking Success Where Others Have Failed

December 20, 2019
Continue Reading

Developing A Smart Inhaler For Optimal Drug Delivery

December 16, 2019
Continue Reading

555: Two Worlds, One Career | Mike Kaseta, CFO, Aerami Therapeutics

December 11, 2019
Continue Reading

10 New Ways MedTech Could Keep Diabetes in Check

November 22, 2019
Continue Reading

Aerami Therapeutics to Present Clinical Data on Dance 501 Inhaled Human Insulin at the 19th Diabetes Technology Meeting

November 11, 2019
Continue Reading

‘Smart’ inhaler can make insulin delivery quick and painless

October 21, 2019
Continue Reading

The Promise of More Effective Inhaled Endocrine-Focused Therapeutics

October 8, 2019
Continue Reading

Drug company’s Bay Area exodus: All about a new CEO, the right talent — and getting out of founder’s living room

September 27, 2019
Continue Reading

Dance Biopharm Announces Rebranding to Aerami Therapeutics Reflecting a Broadened Strategic Focus on Inhaled Therapies for Chronic Diseases

September 25, 2019
Continue Reading

Diabetes relief from an inhaler? Durham company says yes

September 21, 2019
Continue Reading

Posts navigation

Older posts

Categories

  • In The News
  • PRESS RELEASES

Archives

  • 2021
  • 2020
  • 2019
  • 2017

Investor Contact:

Steve Thornton
Aerami Therapeutics, Inc.
(919) 589-8862
sthornton@aerami.com

Media Contact:

Chad Whitaker
Aerami Therapeutics, Inc.
(919) 355-5864
cwhitaker@aerami.com

  • linkedin
  • twitter

2520 Meridian Parkway, Suite 400
Durham, North Carolina 27713
info@aerami.com

© 2020 Aerami Therapeutics.
All Rights Reserved.  Privacy Policy